Oxana Beskrovnaya Sells 2,153 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 2,153 shares of the business’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $11.38, for a total value of $24,501.14. Following the completion of the sale, the insider now owns 195,840 shares in the company, valued at $2,228,659.20. This represents a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Oxana Beskrovnaya also recently made the following trade(s):

• On Tuesday, February 18th, Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10.

Dyne Therapeutics Price Performance

Shares of Dyne Therapeutics stock opened at $12.05 on Friday. Dyne Therapeutics, Inc. has a 1 year low of $11.18 and a 1 year high of $47.45. The firm has a market cap of $1.36 billion, a PE ratio of -3.38 and a beta of 1.11. The company has a 50 day simple moving average of $14.83 and a two-hundred day simple moving average of $25.63.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. As a group, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds have recently added to or reduced their stakes in DYN. FMR LLC raised its holdings in shares of Dyne Therapeutics by 69.7% during the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after buying an additional 3,707,734 shares in the last quarter. Janus Henderson Group PLC grew its position in Dyne Therapeutics by 47.3% during the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock valued at $244,755,000 after acquiring an additional 2,189,339 shares during the last quarter. Jefferies Financial Group Inc. purchased a new position in shares of Dyne Therapeutics during the fourth quarter worth approximately $42,408,000. Norges Bank purchased a new position in shares of Dyne Therapeutics during the fourth quarter worth approximately $22,384,000. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Dyne Therapeutics by 802.3% in the 4th quarter. Point72 Asset Management L.P. now owns 924,681 shares of the company’s stock worth $21,785,000 after acquiring an additional 822,201 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Analyst Upgrades and Downgrades

DYN has been the subject of several analyst reports. Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Scotiabank assumed coverage on Dyne Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price target for the company. Chardan Capital reiterated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research report on Friday, February 28th. Royal Bank of Canada reissued an “outperform” rating and set a $45.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Finally, Piper Sandler reduced their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $48.85.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.